SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update.

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

The researchers also suggest that the plastic chemical exposure itself may lead to heart muscle damage, along with ...

The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, ...

Sadie's relish is expanding into 100 stores. The relish comes in mild and hot, and retails for about $7. It can be used ...

We speak to future food investor Heather Courtney, general partner at Alwyn Capital, about alternative proteins and the ...

When navigating the new product development process, Clemens’ approach is that pork consumers are always seeking ...

Europeans are not eating enough fruits and vegetables, and EU efforts to change this are failing. But the new ’30 plants a ...

Ingredion’s recently created $2.4 billion global texture and healthful solutions segment allows it and the manufacturers with ...

Following a rigorous review of pitches from applicants, Kresko RNAtech has been selected as the winner for its outstanding commitment to advancing the science behind dietary supplements and functional ...

Given Yakult’s record in attaining 2%-4% penetration in many emerging markets, upside potential in the areas outside three first-tier cities—currently representing 80% of Yakult’s target population in ...